Goodwin at HLTH

As public markets reopen, private healthcare and digital health companies are preparing for IPOs while weighing alternative strategic options.

Our panel of legal, financial, and industry experts unpacked the latest IPO readiness considerations — from governance and disclosure prep to evolving regulatory and market expectations.

They explored SPACs, direct listings, and M&A as potential alternatives, and helped founders and investors navigate the most strategic path forward in today’s complex environment.

• Ben Marsh, Partner, Goodwin
• Jennifer Sheng, Head of Healthcare Equity Capital Markets, Citi
• Nishant Jadav, Global Head of Healthcare Services, Citi
• Asher Dewhurst, Managing Director, ICR Healthcare
• Tomer Berkovitz, PhD, Managing Partner, aMoon Fund

Despite a challenging macroeconomic climate, strategic and private equity investors remain active in healthcare M&A.

Our dealmakers and advisors shared how to get transactions across the finish line and where opportunities may lie ahead.

They explored what’s driving deal activity — and what’s stalling it, covering valuation pressures, regulatory scrutiny, antitrust considerations, due diligence trends, and deal structuring in a high-cost capital environment.

• Chris Wilson, Partner, Goodwin
• Adam Dilluvio, Partner, Goodwin
• Matthew Schorr, Managing Director, Lazard